Research explained

Tirzepatide and diabetes prevention: three-year evidence

Updated

What the research shows

SURMOUNT-1 found fewer diagnoses of type 2 diabetes among participants with obesity and prediabetes assigned to tirzepatide than to placebo over 176 weeks. This is evidence of reduced progression during a defined follow-up, not proof that diabetes is permanently prevented or that compounded tirzepatide has the same effect. [1]

Study at a glance

Participants
1,032 participants with both obesity and prediabetes within SURMOUNT-1.
Study design
Randomized, double-blind comparison of weekly tirzepatide or placebo for 176 weeks, followed by 17 weeks off treatment.
Published research
Tirzepatide for Obesity Treatment and Diabetes Prevention

Because the study did not test a compounded product, its results cannot establish the safety, effectiveness or equivalence of a preparation supplied by an individual compounding pharmacy. This article explains published research. It is not medical advice.

Selected findings and how to read them
MeasureReported result or interpretation
Diabetes diagnosis at week 1761.3% with tirzepatide versus 13.3% with placebo.
After 17 weeks off treatment2.4% versus 13.7% had been diagnosed with diabetes.
Meaning of the comparisonAn observed group difference over this study period, not a lifetime guarantee.

Why the starting population matters

Prediabetes describes blood glucose above the normal range but below the diagnostic threshold for diabetes. It is not interchangeable with established type 2 diabetes. A study of progression from one category to the other therefore asks a different question from a study of glucose control in people who already have diabetes.

The participants also had obesity. The trial does not establish the same benefit for everyone with slightly elevated glucose. An individual treatment decision needs the actual diagnosis, other conditions, existing medicines and a discussion of approved options.

For the earlier obesity endpoint, see the original SURMOUNT-1 weight-loss report.

Absolute change, relative change and time

The two percentages at week 176 differ by 12 percentage points. That is the absolute difference between the reported groups. It should not be described as a 12% relative reduction, and the study hazard ratio is not simply another way to express a personal probability.

A hazard ratio incorporates the timing of events during follow-up. A cumulative percentage describes how many people had an event by a particular point. Both can be useful, but a headline should name which measure it uses. A reader cannot turn either group measure into a precise forecast without knowing how closely their circumstances resemble the participants.

What the percentages do—and do not—count

A diagnosis recorded during follow-up is an event, not a measure of how well an existing diabetes diagnosis is controlled. That is why this article keeps progression separate from glucose-lowering claims. The number of new diagnoses and the amount of weight lost are also different outcomes; one should not stand in for the other.

The off-treatment percentages are cumulative outcomes at a later point, rather than the fraction of people who developed diabetes only during the break. Subtracting them casually from the on-treatment numbers could imply a precision the headline figures do not provide. Use the original analysis when asking about timing, and avoid describing the follow-up as a test of a particular taper.

What the off-treatment period adds

The follow-up after treatment stopped is important because a treatment effect and a lasting cure are different propositions. The paper reports outcomes after a defined break; it does not follow every participant for the rest of their life.

Nor does the study establish a self-directed stopping or tapering schedule. Someone who wants to stop because of cost, adverse effects or another reason should discuss a monitoring plan with the clinician managing their glucose. An inexpensive refill cannot replace that plan.

The question of weight regain after withdrawal is explored in the separate withdrawal study.

Benefit belongs beside tolerability

Gastrointestinal events were the most common adverse effects reported with tirzepatide, often during dose escalation. A favorable outcome on diabetes progression does not erase treatment burdens or make the medicine appropriate for everyone.

The practical comparison is not simply treatment versus doing nothing. A clinician can discuss nutrition, activity, other risk factors, monitoring and available medicines together. Trial participants received structured oversight; an online product advertisement is not equivalent oversight.

What this means when comparing care

This research did not test an individual pharmacy’s compounded vial, an additive blend or a different schedule. A provider cannot establish a prevention benefit for its preparation merely by citing SURMOUNT-1. Ask what product is being prescribed and why it is appropriate for your medical needs.

Coverage also follows the product and the applicable criteria, not the presence of the word tirzepatide in a study. Before comparing cash-pay subscriptions, establish whether an approved product is covered for your circumstances.

Our guide explains insurance and branded-access options.

For a wider view, read the evidence behind other benefits.

Questions to discuss with your clinician

  • Does my diagnosis match the population in this study?
  • What would we monitor if treatment starts or stops?
  • Which approved options and coverage pathways apply to my circumstances?

Sources

  1. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine, 2025. PMID: 39536238.

Explore more research or read how we verify published information.